The threat of antimicrobial resistant gonorrhea
In this medfyle
Expert commentary by Nuno Gomes, MD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the EADV Virtual Congress and presented by:
Henry John Christiaan De Vries, MD, PhD
STI outpatient clinic, Amsterdam UMC
Amsterdam, The Netherlands
The content is produced by Infomedica, the official reporting partner of EADV Virtual Congress. The summary text was drafted by Synthesis Editorial Ltd, and reviewed by Martina Lambertini, MD, an independent external expert, and approved by Prof. Brigitte Dréno, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Nuno Gomes, MD
Department of Dermatovenereology of Centro Hospitalar Universitário São João, Porto, Portugal
About the Expert
Nuno Gomes, MD
Department of Dermatovenereology of Centro Hospitalar Universitário São João, Porto, Portugal
Dr. Nuno Gomes completed the Master Degree in Medicine at Instituto Ciências Biomédicas Abel Salazar – University of Porto between 2009 and 2015. In 2013, he attended a clerkship in the Department of Cardiac Surgery at the Medical and Health Science Centre – University of Debrecen, Hungary. In 2014 and 2015, he attended ERASMUS study plan at Palacky University of Olomouc, Czech Republic. He completed the General Residency at Centro Hospitalar do Algarve – Unidade de Faro in 2016. In 2019, he completed a rotation of Oncodermatology at Institut Universitaire du Cancer de Toulouse – Oncopole, France. He currently works at the Department of Dermatovenereology of Centro Hospitalar Universitário São João, Porto, Portugal.
References
1. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011;16(6):19792.
2. Unemo M. The 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults recommends dual antimicrobial therapy. Euro Surveill 2012;17(47):20323.
3. Chisholm SA, Wilson J, Alexander S, et al. An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England. Sex Transm Infect 2016;92(5):365–7.
4. Smolarchuk C, Wensley A, Padfield S, et al. Persistence of an outbreak of gonorrhoea with high-level resistance to azithromycin in England, November 2014 – May 2018. Euro Surveill 2018;23(23):1800287.
5. Wind CM, de Vries E, van der Loeff MFS, et al. Decreased Azithromycin Susceptibility of Neisseria gonorrhoeae Isolates in Patients Recently Treated with Azithromycin. Clin Infect Dis 2017;65(1):37-45.
6. Fifer H, Saunders J, Soni S, et al. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. Int J STDAIDS 2020;31(1):4–15.
7. Kenyon C, Buyze J, Spiteri G, et al. Population-Level Antimicrobial Consumption Is Associated With Decreased Antimicrobial Susceptibility in Neisseria gonorrhoeae in 24 European Countries: An Ecological Analysis. J Infect Dis 2019;221(7):1107–16.
